

Supplemental material

| | |
|--|---|
| Appendix 1. Countries of the Americas region included in the analysis..... | 2 |
| Appendix 2: Availability of guidelines/protocols for the management of NCDs, referred by national NCD programs. Region of the Americas, 20019-2021..... | 3 |
| Appendix 3. Access to NCD services during the COVID-19 pandemic. Americas region, 2020-2021..... | 4 |
| Appendix 4. NCD service disruption due to COVID-19. Region of the Americas, 2021 results.. | 5 |
| Appendix 5. Approaches employed to overcome NCD service disruptions due to COVID-19 Pandemic. Americas Region, 2020-2021..... | 6 |

Appendix 1. Countries of the Americas region included in the analysis

| Country | Population (thousands) | Public health expenditure as % of GDP | NCD Mortality Rate (age-adjusted per 100 000 pop) |
|---|------------------------|---------------------------------------|---|
| Northern America | | | |
| Canada | 38,067.90 | 7.9 | 302 |
| United States of America | 332,915.10 | 8.5 | 408 |
| Mexico, Central America, and Latin Caribbean | | | |
| Belize | 404.9 | 3.9 | 452 |
| Costa Rica | 5,139.10 | 5.5 | 310 |
| Cuba | 11,317.50 | 9.9 | 431 |
| Dominican Republic | 10,953.70 | 2.5 | 508 |
| El Salvador | 6,518.50 | 4.5 | 393 |
| Guatemala | 18,249.90 | 2.1 | 498 |
| Honduras | 10,063.00 | 2.8 | 615 |
| Mexico | 130,262.20 | 2.7 | 466 |
| Nicaragua | 6,702.40 | 5.1 | 548 |
| Panama | 4,381.60 | 4.6 | 335 |
| South America | | | |
| Argentina | 45,605.80 | 5.9 | 436 |
| Bolivia | 11,832.90 | 4.5 | 584 |
| Brazil | 213,993.40 | 4 | 425 |
| Chile | 19,212.40 | 4.6 | 329 |
| Colombia | 51,265.80 | 5.5 | 327 |
| Ecuador | 17,888.50 | 4.2 | 365 |
| Peru | 33,359.40 | 3.3 | 304 |
| Paraguay | 7,219.60 | 2.9 | 448 |
| Uruguay | 3,485.20 | 6.7 | 446 |
| Venezuela | 28,704.90 | 1.7 | 412 |
| Non-Latin Caribbean | | | |
| Antigua and Barbuda | 98.70 | 2.9 | 502 |
| Bahamas | 396.90 | 3.1 | 533 |
| Barbados | 287.70 | 2.9 | 477 |
| Dominica | 74.30 | 4.3 | . |
| Grenada | 113.00 | 1.7 | 619 |
| Guyana | 790.30 | 3.7 | 802 |
| Haiti | 11,541.70 | 0.9 | 839 |
| Jamaica | 2,973.50 | 3.9 | 455 |
| Saint Kitts and Nevis | 54.20 | 2.5 | . |
| Saint Lucia | 184.40 | 2.1 | 516 |
| Saint Vincent and the Grenadines | 111.30 | 3.1 | 537 |
| Suriname | 591.80 | 5.3 | 666 |
| Trinidad and Tobago | 1,403.40 | 3.4 | 439 |

Source: PAHO Core Indicators, 2022

Appendix 2: Availability of guidelines/protocols for the management of NCDs, referred by national NCD programs. Region of the Americas, 20019-2021

| NCD guidelines/protocols | Hypertension | | Diabetes | | Cancer | | Chronic respiratory | | NCD4 Guidelines/protocols | |
|--|--------------|------|----------|------|--------|------|---------------------|------|---------------------------|------|
| | 2019 | 2021 | 2019 | 2021 | 2019 | 2021 | 2019 | 2021 | 2019 | 2021 |
| Availability | 86% | 89% | 97% | 97% | 77% | 89% | 66% | 71% | 54% | 63% |
| Utilized in at least 50% of health care facilities | 73% | 69% | 74% | 74% | 70% | 60% | 74% | 51% | 34% | 40% |
| Last time updated | | | | | | | | | | |
| last 5 years | 23% | 46% | 46% | 63% | 26% | 31% | 14% | 17% | . | . |
| 6 to 10 years | 40% | 26% | 23% | 11% | 34% | 29% | 23% | 23% | . | . |
| >10 years | 20% | 11% | 23% | 14% | 14% | 23% | 20% | 26% | . | . |
| Includes referral criteria | 77% | 77% | 82% | 89% | 85% | 80% | 78% | 60% | 37% | 49% |

Source: WHO NCD Country Capacity Survey, 2019-2021.

Appendix 3. Access to NCD services during the COVID-19 pandemic. Americas region, 2020-2021

| NCD services | Countries R2 (%) | Same countries R1 and R2 (%) | |
|----------------------------|--------------------------|------------------------------|--------------------------|
| | 2021 (n=35 countries) | 2020 (n=29 countries) | 2021 (n=29 countries) |
| Outpatient NCD services | | | |
| Functioning as normal | 34% (12/35) | 24% (7/29) | 34% (10/29) |
| Limited access | 54% (19/35) | 66% (19/29) | 52% (15/29) |
| Suspended | 3% (1/35) | 7% (2/29) | 3% (1/29) |
| Don't know | 6% (2/35) | 0% (2/29) | 7% (2/29) |
| Not applicable/No response | 3% (1/35) | 3% (1/29) | 3% (1/29) |
| Inpatient NCD services | | | |
| Functioning as normal | 40% (14/35) | 52% (15/29) | 41% (12/29) |
| Limited access | 54% (19/35) | 38% (11/29) | 52% (15/29) |
| Suspended | 0% (2/35) | 0% (0/29) | 0% (0/29) |
| Don't know | 6% (2/35) | 7% (2/29) | 7% (2/29) |
| Not applicable/No response | 0% (2/35) | 3% (1/29) | 0% (2/29) |
| Community-based NCD care | | | |
| Functioning as normal | 37% (13/35) | N/A | 41% (12/29) |
| Limited access | 43% (15/35) | N/A | 41% (12/29) |
| Suspended | 11% (4/35) | N/A | 10% (3/29) |
| Don't know | 6% (2/35) | N/A | 7% (2/29) |
| Not applicable/No response | 3% (1/35) | N/A | 0% (2/29) |
| Mobile NCD clinics | | | |
| Functioning as normal | 11% (4/35) | N/A | 10% (3/29) |
| Limited access | 23% (8/35) | N/A | 17% (5/29) |
| Suspended | 17% (6/35) | N/A | 21% (6/29) |
| Don't know | 14% (5/35) | N/A | 14% (4/29) |
| Not applicable/No response | 34% (12/35) | N/A | 38% (11/29) |

Source: WHO NCD Country Capacity Survey, 2019-2021

Note: Round 1 (R1) conducted in 2020 and Round 2 (R2) conducted in 2021.

N/A – not applicable, data for comparison not available between 2020 and 2021.

Appendix 4. NCD service disruption due to COVID-19. Region of the Americas, 2021 results.

| Disruption level | Hypertension management | | Cardio-vascular emergencies | | Cancer screening | | Cancer treatment | | Diabetes and complications | | Asthma | | Urgent dental care | | Rehabilitation | | Palliative care | |
|----------------------|-------------------------|----------------|-----------------------------|----------------|------------------|----------------|------------------|----------------|----------------------------|----------------|----------------|----------------|--------------------|----------------|----------------|------|-----------------|------|
| | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 |
| Not disrupted | 52% (15/29) | 31% (9/29) | 79% (23/29) | 59% (17/29) | N/A | 28% (8/29) | 59% (17/29) | 41% (12/29) | 45% (13/29) | 34% (10/29) | 55% (16/29) | 41% (12/29) | 41% (12/29) | 38% (11/29) | 14% (4/29) | N/A | 24% (7/29) | N/A |
| Partially disrupted | 45% (13/29) | 41% (12/29) | 17% (5/29) | 17% (5/29) | N/A | 41% (12/29) | 28% (8/29) | 34% (10/29) | 52% (15/29) | 45% (13/29) | 28% (8/29) | 31% (9/29) | 41% (12/29) | 34% (10/29) | 38% (11/29) | N/A | 34% (10/29) | N/A |
| Completely disrupted | 0% (0/29) | 7% (2/29) | 0% (0/29) | 0% (0/29) | N/A | 10% (3/29) | 0% (0/29) | 0% (0/29) | 0% (0/29) | 3% (1/29) | 0% (0/29) | 7% (2/29) | 7% (2/29) | 3% (1/29) | 21% (6/29) | N/A | 7% (2/29) | N/A |
| Don't know | 0% (0/29) | 21% (6/29) | 0% (0/29) | 21% (6/29) | N/A | 17% (5/29) | 10% (3/29) | 21% (6/29) | 0% (0/29) | 17% (5/29) | 14% (4/29) | 21% (6/29) | 7% (2/29) | 24% (7/29) | 24% (7/29) | N/A | 31% (9/29) | N/A |
| NA/NR | 3% (1/29) | 0% (0/29) | 3% (1/29) | 3% (1/29) | N/A | 3% (1/29) | 3% (1/29) | 3% (1/29) | 3% (1/29) | 0% (0/29) | 3% (1/29) | 0% (0/29) | 3% (1/29) | 0% (0/29) | 3% (1/29) | N/A | 3% (1/29) | N/A |

Source: WHO NCD Country Capacity Survey, 2019-2021

N/A – not applicable, data for comparison not available between 2020 and 2021.

NR – no response

Appendix 5. Approaches employed to overcome NCD service disruptions due to COVID-19 Pandemic. Americas Region, 2020-2021.

| Approaches to overcome NCD service disruption | Countries R2 (%) | Same countries R1 and R2 (%) | |
|---|-----------------------|------------------------------|-----------------------|
| | 2021 (n=35 countries) | 2020 (n=29 countries) | 2021 (n=29 countries) |
| Triaging to identify priorities | 75% (18/24) | 74% (14/19) | 68% (13/19) |
| Telemedicine deployment to replace in-person consults | 67% (16/24) | 63% (12/19) | 63% (12/19) |
| Redirection of patients to alternate care sites /reorientation of referral pathways | 67% (16/24) | 47% (9/19) | 58% (11/19) |
| Novel dispensing approaches for medicines | 63% (15/24) | 47% (9/19) | 58% (11/19) |
| Task shifting / role delegation | 38% (9/24) | 32% (6/19) | 42% (8/19) |
| Other | 8% (2/24) | 5% (1/19) | 5% (1/19) |
| Integration of several services into single visit | 38% (9/24) | N/A | N/A |
| Self-care interventions where appropriate | 75% (18/24) | N/A | N/A |
| Provision of home-based care where appropriate | 75% (18/24) | N/A | N/A |
| Catch-up campaigns for missed appointments | 25% (6/24) | N/A | N/A |
| Recruitment of additional staff | 67% (16/24) | N/A | N/A |
| Expanding facility hours | 29% (7/24) | N/A | N/A |
| Novel supply chain management and logistics approaches | 33% (8/24) | N/A | N/A |
| Novel prescribing approaches (e.g. tele-prescription, extended drug prescriptions) | 63% (15/24) | N/A | N/A |
| Community communications | 75% (18/24) | N/A | N/A |
| Government removal of user fees | 0% (0/24) | N/A | N/A |

Source: WHO NCD Country Capacity Survey, 2019-2021

N/A – not applicable, data for comparison not available between 2020 and 2021.

NR – no response.